Bacteremia

1		A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial	Bacteremia	Drug: Telavancin Drug: Vancomycin Drug: Daptomycin (and 2 more...)	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment	Remington-Davis Clinical Research Columbus, Ohio, United States
2		Therapeutic Drug Monitoring and Continuous Infusion of Beta-lactam Antibiotics in Patients With Bacteraemia	Bacteremia	Drug: Continuous infusion of beta-lactam antibiotics . Other: Therapeutic drug monitoring of beta-lactam antibiotics.	Allocation: Randomized Intervention Model: Factorial Assignment Masking: Single (Outcomes Assessor) Primary Purpose: Treatment
3		Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness: A Pilot RCT	Bacteremia	Other: 7 days of adequate antibiotic treatment durations Other: 14 days of adequate antibiotic treatment durations	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment	Foothills Hospital Calgary, Alberta, Canada University of Alberta Hospital Edmonton, Alberta, Canada Royal Columbian Hospital Vancouver, British Columbia, Canada (and 14 more...)
4		A New Antibiotic Prophylaxis Regimen to Prevent Bacteremia Following Dental Procedures	Bacteremia	Drug: Amoxicillin-Potassium Clavulanate Drug: Amoxicillin Drug: Chlorhexidine	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Care Provider, Outcomes Assessor) Primary Purpose: Prevention	Hospital Clinico Universitario de Santiago Santiago de Compostela, A Coruña, Spain Santiago de Compostela University Hospital Santiago de Compostela, Coruña, Spain
5		Empirical Antibiotic and Outcome in Community-onset Bacteremia	Bacteremia		Observational Model: Cohort Time Perspective: Prospective	Worapong Nasomsong Bangkok, Thailand
6		Spanish Bacteriemia Cohort 2016: Epidemiology, Clinical Management and Prognosis Factors	Bacteremia		Observational Model: Cohort Time Perspective: Prospective	Public Health Agency Business Hospital de Poniente. El Ejido, Almería, Spain General Hospital of Granollers Granollers, Barcelona, Spain University Hospital Mútua de Terrasa Terrassa, Barcelona, Spain (and 26 more...)
7		Prevalence and Characterization of Diagnostic Error Among Patients With Bacteremia	Bacteremia Sepsis		Observational Model: Other Time Perspective: Retrospective
8		Incidence of Bacteremia Following Argon Plasma Coagulation in Patients With Endobronchial Lesions	Bacteremia		Observational Model: Cohort Time Perspective: Prospective	Meir MC Kfar Saba, Israel
9		Virulence Determinants in S AureusBacteremia	Bacteremia	Other: No intervention	Observational Model: Case Control Time Perspective: Retrospective	Duke University Medical Center Durham, North Carolina, United States
10		Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus AureusBacteremia Receiving Standard-of-Care (SOC) Antibiotics	Bacteremia	Drug: DSTA4637S Drug: Placebo Drug: SOC	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment	Los Angeles Biomedical Research Institute at Harbor-UCLA Torrance, California, United States Tufts Medical Center Boston, Massachusetts, United States Henry Ford Health System Detroit, Michigan, United States (and 14 more...)
11		Detecting Infections Rapidly and Easily forBacteremia Trial (DIREBT)	Bacteremia		Observational Model: Case Control Time Perspective: Prospective	Cooper Medical School Camden, New Jersey, United States
12		Staphylococcus Aureus Bacteraemia in Adults	Staphylococcus Aureus Bacteremia		Observational Model: Cohort Time Perspective: Prospective	Uniklinik Koln Cologne, NRW, Germany Uniklinik Freiburg Freiburg, Germany Univeritatklinikum Schleswig-Holstein Lübeck, Germany (and 21 more...)
13		Staphylococcus Aureus Bacteremia: Impact of an Intervention Program in Improving the Clinical Management and Review of the Clinical and Molecular Epidemiology	Staphylococcus Aureus Bacteremia	Behavioral: Follow recommendations based on scientific evidence to S. aureus bacteremia management Behavioral: Not to follow recommendations based on scientific evidence to S. aureus bacteremia management	Observational Model: Cohort Time Perspective: Prospective	Hospital de Puerto Real Puerto Real, Cádiz, Spain Hospital Costa del Sol Marbella, Málaga, Spain Hospital de Torrecárdenas Almería, Spain (and 13 more...)
14		Antibiotic Durations for Gram-negativeBacteremia	BacteraemiaCaused by Gram-Negative Bacteria	Other: "Fixed long" antibiotic course of 14 days Other: "Fixed short" antibiotic course of 7 days Other: "Individualized duration" of antibiotic therapy	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment	Cantonal Hospital St Gallen St. Gallen, Saint Gallen, Switzerland Lausanne University Hospital Lausanne, Vaud, Switzerland Geneva University Hospitals Geneva, Switzerland
15		A Prospective Observational Study of Patients With Drug Resistant Acinetobacter BaumanniiBacteremia	Acinetobacter Bacteraemia		Observational Model: Cohort Time Perspective: Prospective	Yunlinn NTUH Branch Douliou, Taiwan Far Eastern Memorial Hospital New Taipei, Taiwan National Taiwan University Hospital Taipei, Taiwan
16		PVP Iodine Effect on Post DebridementBacteraemia	Bacteraemia Post Debridement	Drug: Supra- and subgingival rinsing with 10% PVP-iodine Other: Water	Allocation: Randomized Intervention Model: Crossover Assignment Masking: Single (Outcomes Assessor) Primary Purpose: Prevention	Clinic for Preventive Dentistry, Perioodntology and Cariology, University of Zurich Zurich, ZH, Switzerland
17		Safety & Efficacy of Daptomycin Versus Standard of Care (SOC) in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)	Bacteremia	Drug: Daptomycin Drug: Comparator	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment
18		Establish Quantitative PCR to Measure Bacteria Load of the VRE Bacteremia	Bacteremia		Observational Model: Case-Only Time Perspective: Prospective	national Taiwan University Hospital Taipei, Taiwan
19		Clinical Outcomes and Cost of Gram NegativeBacteremia	Gram-negative Bacteremia Bacteremia		Observational Model: Cohort Time Perspective: Prospective	Duke University Medical Center Durham, North Carolina, United States
20		Non-inferiority Trial Comparing Cloxacillin vs Cefazolin in Methicillin-susceptible Staphylococcus Aureus Bacteremia	Bacteremia Due to Methicillin Susceptible Staphylococcus Aureus	Drug: Cloxacillin Drug: Cefazolin	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment	François-Xavier Lescure Paris, France
21		Study of the Impact of the Minimum Inhibitory Concentration and Susceptible Cut-off Points (CLSI, EUCAST, and Pharmacokinetics/Pharmacodynamics)in Prognosis of Bacteremia by Enterobacteriaceae	Bacteremia by Enterobacteriaceae	Other: Microbiological studies	Observational Model: Cohort Time Perspective: Prospective	Hospital Universitario de Bellvitge L'Hospitalet de Llobregat, Barcelona, Spain Hospital Son Espases Palma de Mallorca, Mallorca, Spain Hospital Clínic Barcelona, Spain (and 11 more...)
22		Seven Versus Fourteen Days of Treatment in Uncomplicated Staphylococcus AureusBacteremia	Staphylococcus Aureus Bacteremia	Drug: Antibiotic therapy duration for 7 days	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single (Outcomes Assessor) Primary Purpose: Treatment	Hvidovre Hospital Hvidovre, Copenhagen, Denmark
23		Duration of Antibiotics for the Treatment of Gram-negative Bacilli Bacteremia	Gram Negative Bacteremia	Drug: short-course antibiotic treatment Drug: accepted prolonged antibiotic treatment	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment	Rambam Health Care Center Haifa, Israel Rabin medical center, Beilinson Hospital Petah Tikvah, Israel Policlinico di Modena, Italy Modena, Emilia Romagna, Italy
24		Vancomycin Versus Daptomycin for the Treatment of Methicillin Resistant Staphylococcus Aureus (MRSA) Bacteremia	Bacteremia Due to Staphylococcus Aureus	Drug: Daptomycin Drug: Vancomycin	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment	Singapore General Hospital Singapore, Singapore
25		Ceftobiprole in the Treatment of Hospitalized Patients With Staphylococcus AureusBacteremia	Bacteremia	Drug: ceftobiprole medocaril	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment
26		Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia	Staphylococcus Aureus Bacteremia	Drug: Ceftobiprole medocaril Drug: Daptomycin	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment	6701 Airport Boulevard Mobile, Alabama, United States eStudy Site - Chula Vista - PPDS Chula Vista, California, United States eStudy Site - La Mesa - PPDS La Mesa, California, United States (and 25 more...)
27		Efficacy of Daptomycin Plus Fosfomycin Versus Daptomycin for Treatment of MRSABacteremia	Staph Aureus Methicillin Resistant Bacteremia	Drug: Fosfomycin 2gr/6h iv Drug: Daptomycin 10mg/kg/24h iv	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment	Hospital Universitari de Bellvitge Hospitalet de Llobregat, Barcelona, Spain Hospital Parc Taulí Sabadell, Barcelona, Spain Hospital Universitari Mútua de Terrassa Terrassa, Barcelona, Spain (and 15 more...)
28		The Benefit of FDG PET CT in the Treatment Algorithm of Staphylococcus AureusBacteremia	Staphylococcus Aureus Bacteremia	Procedure: FDG PET CT	Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Diagnostic	Rambam Health Care Campus Haifa, Israel
29		Rapid Identification and Phenotypic Susceptibility Testing for Gram-NegativeBacteremia	Gram-negative Bacteremia	Device: Accelerate PhenoTest™ BC Kit Device: Standard Culture and AST	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single (Care Provider) Primary Purpose: Diagnostic	University of California, Los Angeles Los Angeles, California, United States Mayo Clinic Rochester, Minnesota, United States
30		A Study of the Safety and Efficacy of 514G3 in Subjects Hospitalized With Bacteremia Due to Staphylococcus Aureus	Staphylococcus Aureus Bacteremia	Biological: 514G3 Drug: Placebo Drug: Standard IV antibiotic therapy	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment	XBiotech Investigative Site Columbus, Georgia, United States XBiotech Investigative Site Charlotte, North Carolina, United States
31		Recurrent ESBL-producing EnterobacteriaceaeBacteremia: Risk Factor, Molecular Character and Susceptibility Change	Bacteremia		Observational Model: Case Control Time Perspective: Retrospective	Chang Gung Medical Foundation, Kaohsiung Branch Kaohsiung, Taiwan
32		BALANCE on the Wards: A Pilot RCT	Bacteremia	Other: 7 days of adequate antibiotic treatment Other: 14 days of adequate antibiotic treatment	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment	Hamilton General Hospital Hamilton, Ontario, Canada Kingston General Hospital Kingston, Ontario, Canada The Ottawa Hospital Ottawa, Ontario, Canada (and 3 more...)
33		Treatment of Hemodialysis Catheter-RelatedBacteremia	Hemodialysis Catheter-related Bacteremia	Drug: tigecycline, N-acetylcysteine, heparin combination Device: guide-wire exchange	Allocation: Randomized Masking: None (Open Label)	University of California, San Diego Medical Center San Diego, California, United States
34		Direct Thrombin Inhibitors Versus LMWH in Staphylococcus Aureus Bacteraemia	Staphylococcus Aureus Bacteraemia	Drug: direct thrombin inhibition Drug: enoxaparin	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label)	KUleuven/UZ Gasthuisberg Leuven, Belgium
35		Clinical Trial Comparing Safety and Pharmacokinetics of Standard Antibiotic Therapy, Plus Aurexis® or Placebo, for Treatment of Staphylococcus AureusBacteremia (SAB)	Staphylococcus Aureus Bacteremia	Drug: Aurexis®	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double
36		Daptomycin as Adjunctive Therapy for Staphylococcus Aureus Bacteremia	Methicillin Susceptible Staphylococcus Aureus Septicemia Bacteremia	Drug: Daptomycin Other: Placebo	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment	McGill University Health Centre (Royal Victoria Hospital, Montreal Neurological Hospital, and Montreal General Hospital) Montreal, Quebec, Canada
37		Bacteraemia Secondary to Tooth Extraction: Chlorhexidine Prophylaxis Protocols	Bacteremia Tooth Extraction Status Nos	Drug: 0.2% Chlorhexidine Drug: 1% Chlorhexidine Procedure: Blood extraction (and 2 more...)	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Investigator, Outcomes Assessor) Primary Purpose: Prevention	Department of Stomatology and Maxillofacial Surgery of the Santo Antonio General Hospital Oporto, Portugal Department of Stomatology University of Santiago de Compostela Santiago de Compostela, Galicia/A Coruña, Spain
38		An Oral Amoxicillin-Clavulanate Regimen to Prevent Bacteremia Following Dental Procedures	Bacteraemia Endocarditis	Drug: Amoxicillin Drug: Amoxicillin-Potassium Clavulanate	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single (Participant) Primary Purpose: Prevention	Hospital Clinico Universitario de Santiago Santiago de Compostela, A Coruña, Spain Santiago de Compostela University Hospital Santiago de Compostela, Coruña, Spain
39		IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB	Bacteremia	Drug: Daptomycin Drug: Vancomycin Drug: Ceftaroline	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment	Sharp Grossmont Hospital La Mesa, California, United States Sharp Memorial Hospital San Diego, California, United States
40		Effect of dRAST on Treatment for Bacteremiain Patients With Hematologic Diseases	Hematologic Diseases Bacteremia Sepsis	Diagnostic Test: dRAST Diagnostic Test: Current standard method	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment	Seoul National University Hospital Seoul, Korea, Republic of
41		Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus AureusBacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia	Staphylococcus Aureus Bacteremia Methicillin-resistant Staphylococcus Aureus (MRSA) Bacteremia	Drug: Ceftaroline fosamil	Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment	Investigational Site Birmingham, Alabama, United States Investigational Site Sacramento, California, United States Investigational Site San Francisco, California, United States (and 24 more...)
42		Factors Associated With Increased Risk ofBacteremia and Cholangitis in ERCP With Cholangioscopy	Cholangitis Bacteremia	Procedure: Cholangioscopy	Observational Model: Cohort Time Perspective: Prospective	Baylor College of Medicine Houston, Texas, United States
43		Bacteria Entering the Blood Stream From Tooth Extractions and Tooth Brushing	Bacteremia	Drug: Effect of Amoxicillin on bacteremia following a single-tooth extraction	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Primary Purpose: Prevention	Carolinas Medical Center Dental Clinic Charlotte, North Carolina, United States
44		Procalcitonin Levels as a Predictor ofBacteremia in Febrile Pediatric Oncology Patients-Pilot Study	Cancer Bacteremia		Observational Model: Cohort Time Perspective: Prospective	CAMC Health Systems Charleston, West Virginia, United States
45		Piperacillin/Tazobactam for Bacteremia With Organisms Producing Chromosomally-Encoded AmpC Beta-Lactamase	Bacteremia AmpC Beta-lactamase		Observational Model: Other Time Perspective: Retrospective	University of Pittsburgh Medical Center Pittsburgh, Pennsylvania, United States
46		Bacteremia in Intensive Care Unit (ICU)	Bacteremia and Sepsis Toll-Like-Receptors (TLRs)		Observational Model: Cohort Time Perspective: Prospective	Zakynthinos E Larisa, Mezourlo, Greece
47		Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. AureusBacteremia	Staphylococcus Aureus Bacteremia Staphylococcus Aureus Endocarditis	Biological: CF-301 Drug: Placebo	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment	CF-301-102 Study Site Birmingham, Alabama, United States CF-301-102 Study Site Sacramento, California, United States CF301-102 Study Site Sylmar, California, United States (and 75 more...)
48		Safety Evaluation of Seraph® 100 to ReduceBacteremia in Patients on Hemodialysis	Bacteremia Bacterial Infection	Device: Seraph 100 Filter	Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	Klinikum Braunschweig Braunschweig, Germany Universitaetsklinikum-Frankfurt Frankfurt, Germany Medizinische Hochschule-Hannover Hannöver, Germany Universitatsklinikum Muenster Muenster, Germany
49		Early Infectious Disease Consultations in Staphylococcus Aureus Bacteremia	Staphylococcus Aureus Bacteremia	Other: infectious disease specialist consultation	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Health Services Research	National University Hospital Singapore, Singapore
50		Clinical and Medico-economic Evaluation of a Rapid Test (ePlex-BCID®, GenMark) for the Diagnosis of Bacteremia and Fungemia.	Bacteremia Sepsis Fungemia	Diagnostic Test: Multiplex PCR Diagnostic Test: Current strategy alone	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single (Participant) Primary Purpose: Diagnostic	Grenoble University Hospital Grenoble, France
51		Turkish Prospective Cohort Study on Carbapenem Resistant Klebsiella PneumoniaBacteremia	Klebsiella Pneumonia Bacteremia	Drug: Combination therapy	Observational Model: Cohort Time Perspective: Prospective	Ankara University Ankara, Turkey Başkent University Ankara, Turkey Hacettepe University Ankara, Turkey (and 13 more...)
52		Comparison Trial for Chloraprep Versus Aqueous Chlorhexidine (2%) for the Prevention of Catheter-related Bacteremia	Sepsis Affecting Skin Central Venous Catheter Related Bacteremia	Drug: A (Chloraprep) Drug: B (Clorhexidine 2%)	Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Prevention
53		Comparison of Nephrotoxicity and Hospital Costs in Patients With Methicillin-Resistant Staphylococcus Aureus Bacteremia Who Received Vancomycin Versus Teicoplanin Therapy	Staphylococcus Aureus Bacteremia			Taipei Medical University - WanFang Hospital Taipei, Taiwan
54		Preventing Catheter-related Bacteremia When Administering Injectable Medications in Premature Infants.	Bacteremia Infant, Very Low Birth Weight	Device: Edelvaiss Multiline NEO Device: Standard Infusion Set	Allocation: Randomized Intervention Model: Crossover Assignment Masking: Single (Participant) Primary Purpose: Prevention	Hôpital Nord - CHU d'Amiens Amiens, France Hôpital Côte de Nacre - CHU de Caen Caen, France Hôpital Jeanne de Flandre - CHRU de Lille Lille, France Hôpital Charles Nicolle - CHU de Rouen Rouen, France
55		Vancomycin Versus Daptomycin for the Treatment of Methicillin-resistant Staphylococcus Aureus Bacteremia Due to Isolates With High Vancomycin Minimum Inhibitory Concentrations (MICs)	Bacteremia	Drug: Vancomycin Drug: Daptomycin	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment
56		A Study on the Tolerability and Early Efficacy of hLF1-11 in Patients With Bacteremia Due to S. Epidermidis	Staphylococcal Infections Bacteremia	Drug: human lactoferrin peptide 1-11	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Care Provider, Investigator) Primary Purpose: Treatment	UMC St. Radboud Nijmegen, Gelderland, Netherlands
57		Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis	Endocarditis Bacteremia	Drug: Dalbavancin Drug: Standard of Care	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single (Outcomes Assessor) Primary Purpose: Treatment	Midway Immunology and Research Center Fort Pierce, Florida, United States
58		Imipenem and Sulbactam in the Treatment of Imipenem-resistant Acinetobacter BaumanniiBacteremia	Acinetobacter Bacteraemia		Observational Model: Case Control Time Perspective: Retrospective	Taipei Veterans General Hospital, Taiwan Taipei, Taiwan
59		Prevalence of CVC-associated Sepsis and Use of Blood Cultures in Berlin - Brandenburg	Bacteremia		Observational Model: Cohort Time Perspective: Retrospective	Department of Anesthesiology and Intensive Care Medicine, Campus Virchow-Klinikum and Campus Charité Mitte, Charité - Universitaetsmedizin Berlin Berlin, Germany
60		Diagnosis of Bacteremia/Septicemia and Culture Negative Endocarditis by the Karius Sequencing-Based Infectious Disease Diagnostic Assay	Bacteremia Septicemia		Observational Model: Cohort Time Perspective: Other	Duke University Hospital Durham, North Carolina, United States
61		Daptomycin in the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to S. Aureus	Bacterial Endocarditis Bacteremia	Drug: daptomycin	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment
62		Device for Bacteremia Prevention in Post Cardiac Surgical Intensive Care Unit Patients	Infection Heart; Surgery, Heart, Functional Disturbance as Result Bacteremia	Device: Chlorhexidine flush	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Prevention	Hamilton Health Sciences Hamilton, Ontario, Canada
63		Clinical Impact of Fluoroquinolone Resistance in Bacteremia Caused by Gram-Negative Bacilli of Urinary Tract Origin	Urinary Tract Infection Fluoroquinolone Bacteremia		Observational Model: Other Time Perspective: Retrospective	University of Pittsburgh Medical Center Pittsburgh, Pennsylvania, United States
64		Increasing the Yield of Blood Cultures in Neonates	Bacteremia	Other: 1cc of blood in a single aerobic culture bottle	Allocation: Non-Randomized Intervention Model: Crossover Assignment Masking: None (Open Label) Primary Purpose: Diagnostic
65		Effectiveness of Routine Sterile Gloving in Blood Culture	Bacteremia	Behavioral: Routine sterile gloving	Allocation: Randomized Intervention Model: Crossover Assignment Masking: Single (Outcomes Assessor) Primary Purpose: Diagnostic	Seoul National University Hospital Seoul, Korea, Republic of
66		Taurolidine Lock Solution in the Prevention of Catheter Related Bacteremia	Bacteremia Neoplasms	Device: Taurolock Device: Heparin	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Prevention	Childrens Department of Oncology A4, Aarhus Universityhospital, Skejby Århus N, Denmark
67		A Cluster-randomized Cross-over Trial Evaluating the Comparative Effectiveness of Three Skin Antiseptic Interventions	Bacteremia	Drug: Iodine tincture Drug: Chlorhexidine gluconate Drug: Povidone iodine	Allocation: Randomized Intervention Model: Crossover Assignment Masking: Double (Participant, Outcomes Assessor) Primary Purpose: Prevention
68		The Value of sTREM-1, PCT, and CRP as Markers for the Detection of Sepsis andBacteremia Among Patients With a FUO	SIRS Sepsis Bacteremia		Observational Model: Case Control Time Perspective: Prospective	Chinese PLA General Hospital Beijing, Beijing, China
69		Blood Cultures's Profitability in Intensive Care Unit	Bacteremia		Observational Model: Other Time Perspective: Prospective	Hopsital Universitario de Getafe Getafe, Madrid, Spain
70		T2Bacteria Panel Pivotal Study	Bacteremia		Observational Model: Cohort Time Perspective: Prospective	Henry Ford Health System Detroit, Michigan, United States University of Pittsburgh Medical Center Pittsburgh, Pennsylvania, United States Rhode Island Hospital Providence, Rhode Island, United States
71		Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen	Sepsis Bacteremia	Drug: cefepime	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Investigator, Outcomes Assessor) Primary Purpose: Treatment	Hospital San Juan de Dios Rionegro, Antioquia, Colombia Clinica Palermo Bogota, DC, Colombia Fundacion San Carlos Bogota, DC, Colombia (and 4 more...)
72		Phase IIa Clinical Study of N-Rephasin® SAL200	Staphylococcus Aureus Bacteremia Anti-Bacterial Agents	Biological: N-Rephasin® SAL200 Other: Placebo	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment	Seoul National University Bundang Hospital Seongnam-si, Gyeonggi-do, Korea, Republic of Seoul National University Hospital Seoul, Korea, Republic of
73		Efficacy of 2% Chlorhexidine Gluconate in 70% Alcohol Compare 10% Povidone Iodine in Blood Culture in Children	Bacteremia	Drug: 2% chlorhexidine gluconate in 70% alcohol Drug: 10%povidone iodine	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Prevention	Thammasat University hospital Klong luang, Pathumthanii, Thailand
74		Study of the Performance of the KeyPath MRSA/MSSA Blood Culture Test - BTA	Bacteremia		Observational Model: Case Control Time Perspective: Prospective	University of Arizona, Infectious Disease Research Tuscon, Arizona, United States UCLA Clinical Laboratory Los Angeles, California, United States Medical University of South Carolina Charleston, South Carolina, United States
75		Hub Cleansing to Prevent Hub Infection	Bacteremia	Other: 15 second scrub Other: 5 second scrub Drug: 3.15% chlorhexidine/70% isopropyl alcohol Drug: 70% isopropyl alcohol	Allocation: Randomized Intervention Model: Factorial Assignment Masking: Double (Participant, Care Provider) Primary Purpose: Prevention	Rush University Medical Center Chicago, Illinois, United States
76		Multicenter Blood Culture Quality Improvement	Bacteremia	Other: Blood Culture QI Program	Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Prevention	Vanderbilt Emergency Medicine Nashville, Tennessee, United States Vanderbilt University Medical Center Emergency Medicine Nashville, Tennessee, United States
77		Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection	Bacteremia	Drug: Vancomycin	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment	University of Alabama, Birmingham Birmingham, Alabama, United States David Geffen School of Medicine UCLA Los Angeles, California, United States University of Colorado Denver, Colorado, United States (and 12 more...)
78		Ethanol Lock for the Salvage of Infected Long-term Vascular Access	Bacteremia	Drug: Ethanol-lock therapy Drug: Antibiotic-lock	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single (Outcomes Assessor) Primary Purpose: Treatment	Fondazione IRCCS Policlinico "San Matteo" Pavia, PV, Italy
79		Prospective Study Into the Performance of the MicroPhage S. Aureus/MSSA/MRSA Test Direct From Blood Culture Positives	Bacteremia	Device: MicroPhage S. aureus/MSSA/MRSA Blood Culture Test	Time Perspective: Prospective
80		Daptomycin Pharmacokinetics in Continuous Veno-venous Hemodiafiltration	Bacteremia	Drug: Daptomycin	Allocation: Non-Randomized Intervention Model: Factorial Assignment Masking: None (Open Label) Primary Purpose: Treatment	Medical Intensive Care Unit, University Hospital Zurich Zurich, Switzerland
81		Amoxicillin to Prevent Bacteria and Inflammatory Biomarkers After Intensive Periodontal Therapy	Chronic Periodontitis Bacteremia	Drug: Amoxicillin Other: Placebo	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment	Luis Antonio Noriega Frontado Bogotá, Bogotá D.C, Colombia
82		The Impact of Material on Microbiota in Association With Tongue and Lip Piercing	Bacteremia	Device: piercings of four different materials	Observational Model: Case Control Time Perspective: Prospective	Innsbruck Medical University Innsbruck, Austria
83		Prevention of Bacteremia Induced by Debridement of Pressure Ulcer	Pressure Ulcers Bacteremia		Observational Model: Defined Population Primary Purpose: Screening Time Perspective: Longitudinal Time Perspective: Prospective	Herzog Hospital Jerusalem, Israel
84		Central Venous Catheter Lock Solution	Bacteremia	Other: citrate Other: heparin	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Investigator, Outcomes Assessor) Primary Purpose: Prevention	Department of Dialysis Tuzla, TK, Bosnia and Herzegovina
85		Impact MRSA -PCR on Patient Management	MRSA Bacteremia	Diagnostic Test: Polymerase Chain Reaction of Methicillin Resistant Staphyloccus Aureus	Observational Model: Cohort Time Perspective: Retrospective	Groupe Hospitalier Paris Saint Joseph Paris, Ile-de-France, France
86		Prophylactic Antimicrobial Catheter Lock	Bacteremia	Drug: Heparin 1000U/mL Drug: 4% Sodium Citrate with Gentamicin 320 mcg/mL	Allocation: Randomized Intervention Model: Single Group Assignment Masking: Double (Participant, Care Provider) Primary Purpose: Treatment	Satellite Healthcare, Inc Mountain View, California, United States
87		Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia(MK-3009-029)	Bacteremia Soft Tissue Infections Skin Diseases, Infectious	Drug: Daptomycin	Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	Japan Community Health Care Organization Chukyo Hospital ( Site 0030) Nagoya, Aichi, Japan Japan Community Health care Organization Kyushu Hospital ( Site 0016) Kitakyushu, Fukuoka, Japan Maebashi Red Cross Hospital ( Site 0012) Maebashi, Gunma, Japan (and 13 more...)
88		The Only Blood Culture for Diagnosis ofBacteremia - Comparative Study of Practice	Bloodstream Infection	Procedure: Single-sampling strategy vs multi-sampling strategy for the diagnosis of bacteremia	Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Diagnostic
89		Safety and Efficacy of Dalbavancin Versus Vancomycin in the Treatment of Catheter-Related Bloodstream Infections	Bacteremia	Drug: dalbavancin	Allocation: Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	Wellstar/Kennestone Hospital Marietta, Georgia, United States
90		Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness	Bacteremia Intensive Care Critically Ill (and 3 more...)	Other: 7 days of adequate antibiotic treatment Other: 14 days of adequate antibiotic treatment.	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment	Cabrini Health Melbourne, Australia Dandenong Hospital- Monash Health Melbourne, Australia Monash Medical Centre Melbourne, Australia (and 39 more...)
91		Efficacy of a Short-term Sequential Therapy in Non-complicated Catheter Related Bacteremiaby Methicillin- Susceptible S.Aureus.	Staphylococcus	Drug: Cloxacilin Drug: Cloxacillin Drug: Levofloxacin	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment	Hospital de Jerez de la Frontera Jerez de la Frontera, Cádiz, Spain Hospital Costa del Sol Marbella, Málaga, Spain Hospital Universitario Reina Sofía Córdoba, Spain (and 8 more...)
92		HeRO Vascular Access Device BacteremiaStudy	Hemodialysis	Device: HeRO Vascular Access Device	Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment	University of Miami / Cedars Medical Center Miami, Florida, United States St. Joseph's Hospital Atlanta, Georgia, United States Southern Illinois University Springfield, Illinois, United States (and 4 more...)
93		Chart Review of Outcome of Treatment for S. Aureus Bacteremia	Staphylococcus Aureus		Observational Model: Ecologic or Community Time Perspective: Retrospective	Michael E. DeBakey Veterans Affairs Medical Center Houston, Texas, United States
94		Alcohol Locks for the Prevention of Tunneled Catheter-related Infections	Bacteremia	Procedure: Alcohol-lock Drug: placebo-lock	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Prevention	Erasmus Medical Center Rotterdam, Netherlands
95		Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment	Complicated Skin and Skin Structure Infections S. Aureus Bacteremia Renal Impairment	Drug: Vancomycin Drug: Daptomycin Drug: Semi-Synthetic Penicillin	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single (Outcomes Assessor) Primary Purpose: Treatment	Azusa, California, United States Los Angeles, California, United States Torrance, California, United States (and 7 more...)
96		Predictive Value of Procalcitonin forBacteremia in the ICU	Sepsis Procalcitonin	Diagnostic Test: procalcitonin measurement	Observational Model: Cohort Time Perspective: Retrospective	Rijnstate hospital Arnhem, Gelderland, Netherlands
97		Safety and Bacteraemia Between Peripherally Inserted and Central Inserted Catheters.	Catheter Related Infections	Device: CVC Device: PICC	Allocation: Randomized Intervention Model: Factorial Assignment Masking: None (Open Label) Primary Purpose: Treatment	Hospital de la Santa Creu i Sant Pau Barcelona, Spain
98		Bloodstream Infections in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis Staphylococcus Aureus Bacteremia	Other: Risk factors in RA cohort Other: Risk factors in general population	Observational Model: Cohort Time Perspective: Retrospective
99		Successful Treatment of Maternal Listeria Monocytogenes Bacteremia in the First Trimester	Listeria Monocytogenes	Drug: Ampicillin Injection	Observational Model: Case-Only Time Perspective: Retrospective	Far Eastern Memorial Hospital New Taipei, Taiwan
100		Procalcitonin Level as a Surrogate for Catheter-related Blood Stream Bacteremia Among Hemodialysis Patients	Hemodialysis Catheter Infection		Observational Model: Cohort Time Perspective: Prospective	New jeddah clinic Hospital Jeddah, Saudi Arabia